The Renoprotective Effect of Linagliptin in Type 2 Diabetic Patients with Severely Increased Albuminuria

Authors

  • Firoozeh Moeinzadeh Isfahan Kidney Diseases Research Center, Al-zahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran Author
  • Bijan Iraj Department of Internal Medicine, Medical School, Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Author
  • Mojgan Mortazavi Isfahan Kidney Diseases Research Center, Al-zahra Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran Author
  • Pouria Ramezani Department of Internal Medicine, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran Author

Abstract

Introduction. Previous studies have suggested that linagliptin may represent renoprotective effects besides its anti-hyperglycemic properties in patients with type 2 diabetes. However, there is a lack of decisive evidence to support this assumption. This study aimed to address the effect of linagliptin in type 2 diabetic patients with severely increased albuminuria. Methods. In this randomized double-blind, placebo-controlled clinical trial, type 2 diabetic patients with severely increased albuminuria (albuminuria ≥ 300 mg/24 h) were enrolled. Patients were randomized to linagliptin (5 mg/d) and placebo based on a computer-generated list of random numbers. Biochemical (fasting blood sugar (FBS) (mg/dL), hemoglobin A1c (HbA1c) (%), proteinuria (mg/24h), blood urea nitrogen (BUN) (mg/dL), serum creatinine (mg/dL)) and clinical variables (weight (kg), systolic, and diastolic blood pressure (mmHg)) were measured at baseline and 3 and 6 months post intervention. Results. At baseline, no statistically significant difference was detected in demographic characteristics between the two groups (P > .05). A significant decrease was observed in proteinuria, FBS, weight, SBP, and DBP in the intervention group after 6 months (Ptime < .05), however; none of the clinical and biochemical variables showed a significant difference between groups after 6 months (Pgroup > .05). Conclusion. Linagliptin may serve as a renoprotective therapeutic option in diabetic patients with severely increased albuminuria due to its role in proteinuria reduction. Results of this study can be used for future large-scale, long-term studies investigating the renoprotective effects of linagliptin in patients with diabetic nephropathy.

 

DOI: 10.52547/ijkd.6110

Downloads

Download data is not yet available.

Downloads

Published

2021-09-26

Issue

Section

ORIGINAL | Kidney Diseases

How to Cite

The Renoprotective Effect of Linagliptin in Type 2 Diabetic Patients with Severely Increased Albuminuria. (2021). Iranian Journal of Kidney Diseases, 15(5), 344-350. https://www.ijkd.org/index.php/ijkd/article/view/6110

Most read articles by the same author(s)